Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 13/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756847 | 0.85 | HTT (0.56) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3761681 | 0.85 | PIK3CD (0.54) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3764741 | 0.82 | PIK3CA (0.52) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3759318 | 0.80 | HTT (0.50) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3764678 | 0.79 | MAP2K2 (0.49) | HTTHIF1APIK3CATSHRMAP2K2 | |
| SCHEMBL16161712 | 0.77 | HTT (0.47) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3761426 | 0.75 | HTT (0.45) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3763104 | 0.73 | HTT (0.43) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL3762262 | 0.73 | HTT (0.46) | HTTHIF1APIK3CDPIK3CAPIK3CB | |
| SCHEMBL303269 | 0.72 | HTT (1.00) | HTTHIF1APIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | HTT 1234/4885HIF1A 2929/4885PIK3CD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.